Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Aminopeptidase N: the glucocorticoid gateway linking chronic stress to ferroptosis resistance in liver cancer
Maowu Luo, Weibo Luo
Maowu Luo, Weibo Luo
View: Text | PDF
Commentary

Aminopeptidase N: the glucocorticoid gateway linking chronic stress to ferroptosis resistance in liver cancer

  • Text
  • PDF
Abstract

Chronic stress triggers a range of physiological responses that could dysregulate the immune system and metabolic processes, thereby increasing susceptibility to various diseases. In this issue of the JCI, Wu et al. identified a metabolic bridge between chronic stress and liver cancer progression. Chronic stress–induced glucocorticoids promoted aminopeptidase N (ANPEP) expression and subsequent reprogramming of amino acid metabolism, leading to increased liver cancer growth and metastasis. ANPEP facilitated stabilization of the cystine-glutamate transporter system Xc– and increased l-cystine influx, thereby enhancing cellular antioxidant capacity to prevent ferroptosis. Silencing ANPEP in combination with sorafenib treatment showed a synergistic inhibitory effect on liver cancer progression. These findings uncover ANPEP as a valuable target for therapeutic interventions to treat patients with liver cancer experiencing chronic stress.

Authors

Maowu Luo, Weibo Luo

×

Figure 1

Chronic stress–induced ANPEP drives ferroptosis resistance in liver cancer.

Options: View larger image (or click on image) Download as PowerPoint
Chronic stress–induced ANPEP drives ferroptosis resistance in liver canc...
(A) Wu et al. (11) modeled chronic stress–mediated activation of the hypothalamic-pituitary-adrenal axis using chronic restraint stress. Stress-induced GCs mediated nuclear translocation of NR3C1, activating ANPEP transcription in liver cancer cells. (B) Wu et al. showed that ANPEP interacted with SLC3A2, a transmembrane subunit of the l-cystine/glutamate antiporter system Xc– (which also contains the subunit SLC7A11 shown in the figure). This interaction prevented SLC3A2 from undergoing MARCH8-mediated lysosome-dependent degradation, thereby increasing synthesis of the intracellular antioxidant GSH and protecting liver cancer cells against ferroptosis. (C) Potential therapeutic strategies for liver cancer may include targeting the NR3C1/ANPEP/SLC3A2 axis or implementing psychotherapy to reduce stress, sensitizing tumors to ferroptosis-inducing anticancer therapies.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts